• Vir Biotechnology plans an underwritten public offering of common stock, with all shares offered by the company.
• Underwriters will receive a 30-day option to buy additional shares totaling up to 15% of the offering.
• Leerink Partners, Morgan Stanley and Evercore ISI are bookrunning managers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611121608BIZWIRE_USPR_____20261112_BW431217) on November 12, 2026, and is solely responsible for the information contained therein.